Filing Details

Accession Number:
0001209191-21-009368
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-02-10 17:56:51
Reporting Period:
2021-02-08
Accepted Time:
2021-02-10 17:56:51
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
879407 Arrowhead Pharmaceuticals Inc. ARWR Pharmaceutical Preparations (2834) 460408024
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1627183 Patrick O'brien 177 E. Colorado Blvd
Suite 700
Pasadena CA 91105
General Counsel No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-02-08 90,000 $5.22 383,375 No 4 M Direct
Common Stock Disposition 2021-02-08 7,961 $86.72 375,414 No 4 S Direct
Common Stock Disposition 2021-02-08 31,255 $88.08 344,159 No 4 S Direct
Common Stock Disposition 2021-02-08 45,348 $88.88 298,811 No 4 S Direct
Common Stock Disposition 2021-02-08 5,436 $89.66 293,375 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2021-02-08 90,000 $0.00 90,000 $5.22
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
60,000 2015-06-02 2024-12-02 No 4 M Direct
Footnotes
  1. The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.26 to$87.11, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of ArrowheadPharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of sharessold at each separate price within the ranges set forth in this footnote of this Form 4.
  2. The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.43 to$88.42, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of ArrowheadPharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of sharessold at each separate price within the ranges set forth in this footnote of this Form 4.
  3. The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.44 to$89.41, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of ArrowheadPharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of sharessold at each separate price within the ranges set forth in this footnote of this Form 4.
  4. The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.45 to$89.85, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of ArrowheadPharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of sharessold at each separate price within the ranges set forth in this footnote of this Form 4.
  5. Represents the first vesting date. Option vested over four years from date of grant.